Style | Citing Format |
---|---|
MLA | Ardestani ME, et al.. "High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial." Tanaffos, vol. 23, no. 2, 2024, pp. 156-162. |
APA | Ardestani ME, Nasresfahani M, Mirmohammad Sadeghi FS, Azizkhani R, Heydari F (2024). High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial. Tanaffos, 23(2), 156-162. |
Chicago | Ardestani ME, Nasresfahani M, Mirmohammad Sadeghi FS, Azizkhani R, Heydari F. "High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial." Tanaffos 23, no. 2 (2024): 156-162. |
Harvard | Ardestani ME et al. (2024) 'High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial', Tanaffos, 23(2), pp. 156-162. |
Vancouver | Ardestani ME, Nasresfahani M, Mirmohammad Sadeghi FS, Azizkhani R, Heydari F. High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial. Tanaffos. 2024;23(2):156-162. |
BibTex | @article{ author = {Ardestani ME and Nasresfahani M and Mirmohammad Sadeghi FS and Azizkhani R and Heydari F}, title = {High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial}, journal = {Tanaffos}, volume = {23}, number = {2}, pages = {156-162}, year = {2024} } |
RIS | TY - JOUR AU - Ardestani ME AU - Nasresfahani M AU - Mirmohammad Sadeghi FS AU - Azizkhani R AU - Heydari F TI - High-Flow Nasal Cannula Versus Conventional Oxygen Therapy for Patients With Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial JO - Tanaffos VL - 23 IS - 2 SP - 156 EP - 162 PY - 2024 ER - |